Cannabis and insomnia: what the research actually says

Walk into almost any dispensary in Burlington and you will find products gestured toward sleep. A gummy with "PM" in the name. A tincture described as "calming." An infused beverage wearing a half-moon on its label. The implication is clear even when the claim, legally, cannot be.

Vermont's Cannabis Control Board prohibits health claims on cannabis products, which is why retail signage reads "wind-down" and "chill" instead of "treats insomnia." But plenty of customers arrive hoping cannabis will do exactly that: put them under, keep them there, and stop 3 a.m. from feeling like the most productive hour of the day.

So what does the evidence actually support? Less than the marketing implies, more than the reflexive skeptics allow, and nothing as simple as "indica for sleep."

What the research says — and doesn't

The honest answer is that the clinical research on cannabis and sleep is thin, methodologically inconsistent, and often funded in ways that reward a quick read of the abstract over careful scrutiny of the methods. Most of what we know comes from self-report surveys, small observational studies, and research conducted in contexts — medical programs, controlled lab settings — that may not generalize to someone buying an edible on a Friday night.

That said, some consistent findings have emerged. THC, at lower doses, appears to reduce sleep onset latency — the time it takes to fall asleep. For people managing chronic pain, anxiety, or PTSD, that's not nothing. Several studies have also found that cannabis use is associated with reduced REM sleep, the stage where most dreaming and emotional processing occurs. Whether that's a benefit or a cost depends entirely on why you're not sleeping in the first place.

CBD's role is murkier. Early research suggested it might have alerting effects at low doses and sedating effects at higher ones, which makes consistent guidance nearly impossible — and largely explains why "CBD for sleep" remains contested even among researchers who are otherwise sympathetic to the compound.

The CBN overclaim

Ask about sleep in any Vermont shop and someone will almost certainly mention CBN — cannabinol, a minor cannabinoid that appears as THC degrades over time. The story: CBN is the "sleepy cannabinoid," the reason old cannabis made people drowsy.

The problem is the evidence doesn't really support this. The original research dates to the 1970s, involved very few subjects, and included alcohol as a confounding variable. More recent reviews have been skeptical of CBN's standalone sedative effects. What probably made aged, oxidized cannabis feel sedating was a combination of degraded THC, shifted terpene profiles, and the general entropy of the plant — not CBN operating as a discrete sleep agent.

That hasn't slowed CBN's a Vermont dispensary as one of the more aggressively marketed minor cannabinoids in the sleep category. If you want a grounded look at what each cannabinoid actually does and doesn't do, the site glossary is worth a read before you build a nighttime routine around any single compound.

Terpenes: more plausible, still not settled

The terpene argument for sleep is more credible than the CBN argument, even if the science still lags behind the enthusiasm. Myrcene — one of the most prevalent terpenes in cannabis — also appears in hops, and hop extract has a reasonable body of evidence behind it for mild sedation. Linalool, the primary terpene in lavender, has been studied for anxiolytic effects. Both appear frequently in cultivars anecdotally associated with relaxation.

The honest caveat: we don't yet know whether terpene concentrations in a commercially produced cannabis product are sufficient to produce the same effects observed in aromatherapy or supplement research. The entourage effect — the hypothesis that cannabinoids and terpenes work synergistically — remains more compelling than proven. If you're using terpene profiles to guide your choices, the strain match tool lets you filter by reported terpene content, which is a more defensible approach than relying on the indica/sativa/hybrid framework, which has increasingly little taxonomic backing at the cultivar level.

The tolerance problem, which nobody's marketing mentions

Whatever sleep benefit cannabis provides tends to diminish with regular use. THC tolerance develops relatively quickly, and disruption to REM architecture can compound over time. Longer-term, heavier users often report that cannabis has become necessary for sleep without actually improving it — a maintenance dose rather than a treatment.

This is worth sitting with before you formalize a nightly cannabis routine. Tolerance breaks are real and can be uncomfortable. If you find yourself using progressively more and sleeping progressively worse, that's the pattern to watch for. The what to do if you're too high guide covers the acute side of overconsumption, but the chronic pattern deserves its own honest reckoning — ideally with a clinician who approaches cannabis without reflexive dismissal or financial interest in the answer.

What probably works, for whom

The most defensible position, based on current evidence: cannabis can serve as a useful short-term sleep aid for specific people — those dealing with pain, PTSD, or acute anxiety — at low to moderate THC doses, taken 30–60 minutes before bed. Edibles in the 2.5–5mg range are a reasonable starting point. They have a longer and less predictable onset than inhalation but more stable duration, which tends to matter more once you're actually trying to stay asleep.

Inhalation works faster but wears off faster, which can contribute to early-morning waking as THC clears the system. Some users find that a small edible supplemented with a modest amount of flower produces better results than either alone, though this adds variables to an already complicated equation and makes isolating what's working considerably harder.

Vermont dispensaries — whether you're stopping into Winooski Organics in Winooski or heading north to Lake Effect Cannabis — can speak to what products customers have responded well to. That's anecdote, not clinical evidence, but it's useful anecdote. Ask specifically about onset time, duration, and whether the product has published terpene data.

What no shop can do — legally or practically — is tell you cannabis will fix your insomnia. If you've been struggling with sleep for months or years, the evidence base for cognitive behavioral therapy for insomnia is considerably more robust than anything currently in a display case, cannabis included. That's not an argument against trying cannabis; it's an argument for accurate expectations, which is the most useful posture a consumer can bring to any product in any category.